Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302
Glenmark Pharmaceuticals S.A. and Harbour BioMed announced that they have entered into an exclusive license agreement for the Greater China territory to develop, manufacture and…
Read More...
Read More...
